Takeda Pharmaceutical Company Limited

Cardurion Pharmaceuticals, LLC

The Rockefeller University

Yuta Tanaka

Tomohiro Okawa

Yasufumi Miyamoto

Satoshi Sasaki

Keiko Kakegawa

Zenyu Shiokawa

Takuto Kojima

Junya Shirai

Shinichi Imamura

Xiaolun Wang

Nicholas Scorah

Minoru Yoshida

Yasutomi Asano

John S Tyhonas

Phong H Vu

Terufumi Takagi

Mark Sabat

Tzu-Tshin Wong

Shuji Kitamura

Akito Shibuya

Yasuhiro Hirata

Joanne Miura

Rei Okamoto

Haixia Wang

Yoichi Nishikawa

Osamu Kurasawa

Nobuyuki Matsunaga

Yoshito Terao

Takafumi Yukawa

Lily Kwok

Mallareddy Komandla

Tomohiro Ohashi

Kazuko Yonemori

Takeshi Yoshikawa

Naoki Iwamura

Takashi Nakahata

Hiroki Takahagi

Ryosuke Arai

Paul Tanis

Bunnai Saito

Osamu Sano

Takeshi Yamamoto

Minoru Nakamura

Tatsuki Koike

Masaki Seto

Kazuaki Takami

Yuhei Miyanohana

Masaki Daini

Masataka Murakami

Minoru Sasaki

Masaki Ogino

Hideki Furukawa

Satoshi Mikami

Zenichi Ikeda

Eiji Kimura

Makoto Fushimi

Fumiaki Kikuchi

Michael Andrew Foley

Moriteru Asano

Kazuyoshi Aso

Takahito Kasahara

Nao Morishita

Tarun M Kapoor

Yoshiyuki Fukase

Yayoi Yoshitomi

Yashuhiro Hirata

Sachie Takashima

Yuki Hanya

Florian Pünner

Arai Ryosuke

The present invention provides a compound having a glucosylceramide lowering action (e.g., promoting glucosylceramide metabolism, inhibition of glucosylceramide synthesis, promoting glucosylceramide catabolism, etc.), which is expected to be useful as an agent for the prophylaxis or treatment of lysosome diseases (e.g., Gaucher's disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

Heterocyclic compound

The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification,or a salt thereof.

Substituted amines for treating cardiac diseases

Compounds of formula: are useful as antitumor agents. In these compounds, Ris (a) (C-C) hydrocarbyl, (C-C)halohydrocarbyl, (C-C)hydroxyalkyl, or or Ris (b) in which Q and A are linkers and Ar is optionally substituted monocyclic or bicyclic aryl or heteroaryl.

Pyrazoloquinazolinone antitumor agents

The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

The present invention relates to a compound which can be useful for the treatment or prevention of SPT-related diseases including cancer and congenital diseases associated with sphingolipid accumulation (including Niemann-Pick disease).

Provided is a compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and is useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, (excluding N-(4-bromo-3-(1H-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(imidazo[1,2-a]pyridin-5-yl)acetamide) or a salt thereof.

The present invention provides a fused heterocycle derivative having a strong Smo inhibitory activity, and use thereof. Specially, the present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or salt thereof, and a medicament containing the compound or a prodrug thereof, which is an Smo inhibitor or an agent for the prophylaxis or treatment of cancer.

Fused heterocyclic ring derivative and use thereof

Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer

Growing community of inventors

Kanagawa, Japan

Yuta Tanaka